Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - ertapenem sodium - concentrate for solution for infusion - ertapenem sodium 1 g - antibacterials for systemic use

Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - a, s - solution for injection/infusion - ampicillin sodium 1 g sulbactam sodium 0.5 g - antibacterials for systemic use

Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - a, s - powder for solution for injection/infusion - ampicillin sodium 2 g sulbactam sodium 1 g - antibacterials for systemic use

Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - meropenem - powder for solution for infusion or injection - meropenem 500 mg - antibacterials for systemic use

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - tolvaptan - inappropriate adh syndrome - diuretics, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - tolvaptan (unii: 21g72t1950) (tolvaptan - unii:21g72t1950) - tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 meq/l or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and syndrome of inappropriate antidiuretic hormone (siadh). limitations of use patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. it has not been established that raising serum sodium with tolvaptan tablets provides a symptomatic benefit to patients. tolvaptan is contraindicated in the following conditions: - patients with autosomal dominant polycystic kidney disease (adpkd) outside of fda-approved rems [see warnings and precautions (5.2)] - unable to sense or respond to thirst - hypovolemic hyponatremia - taking strong cyp3a inhibitors [see warnings and precautions (5.5)] - anuria - hypersensitivity (e.g., anaphylactic shock

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - tolvaptan (unii: 21g72t1950) (tolvaptan - unii:21g72t1950) - tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 meq/l or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and syndrome of inappropriate antidiuretic hormone (siadh). limitations of use: patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. it has not been established that raising serum sodium with tolvaptan tablets provide a symptomatic benefit to patients. tolvaptan tablets are contraindicated in the following conditions: • patients with autosomal dominant polycystic kidney disease (adpkd) outside of fda-approved rems [see warnings and precautions ( 5.2)] • unable to sense or respond to thirst • hypovolemic hyponatremia

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - captan - water dispersible granule - captan carboximide active 900.0 g/kg - fungicide - almond | apple | grape | ornamental seedling | pear | rose | stone fruit | strawberry | tobacco seedling | turf | apricot | cher - anthracnose - colletotrichum acutatum | black spot | black spot on grapes - elsinoe ampelina | blossom blight - monilinia laxa | blossom blight - sclerotinia laxa | brown patch | brown rot | damping off | downy mildew | gloeosporium fruit rot | grey mould - botrytis cinerea | leaf blight | leaf blight - phomopsis viticola | nut scab | phytophthora fruit rot | scorch | shot hole | anthracnose | botrytis blight | botrytis rot | brown rot | bunch rot | fusarium spp. | helminthosporium spp. | phomopsis cane | rhizoctonia spp. | scab | sclerotinia spp.

New Zealand - English - Ministry for Primary Industries

adria new zealand ltd - captan - captan 800 g/kg - fungicide

United States - English - NLM (National Library of Medicine)

apotex corp. - tolvaptan (unii: 21g72t1950) (tolvaptan - unii:21g72t1950) - tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 meq/l or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and syndrome of inappropriate antidiuretic hormone (siadh). patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. it has not been established that raising serum sodium with tolvaptan tablets provides a symptomatic benefit to patients. tolvaptan tablets are contraindicated in the following conditions: - patients with autosomal dominant polycystic kidney disease (adpkd) outside of fda-approved rems [see warnings and precautions (5.2)] - unable to sense or respond to thirst - hypovolemic hyponatremia - taking strong cyp3a inhibitors [see warnings and precautions (5.5)] - anuria - hypersensitivity (e.g., anaphylactic shock, rash gen